Effect of pyridoxal 5'-phosphate on human neutrophil aggregation in vitro.
Pyridoxal 5'-phosphate inhibited polymorphonuclear leukocyte aggregation in vitro in a dose-dependent fashion at concentrations ranging from 0.5 to 0.001 mmol/l. At pyridoxal 5'-phosphate concentrations between 0.4 and 0.5 mmol/l mean inhibition of aggregation was about 50%-60%. In this range, and at lower pyridoxal 5'-phosphate concentrations, phorbol myristate acetate-activated polymorphonuclear leukocytes showed a normal increase in volume, whereas swelling was inhibited at higher concentrations of pyridoxal 5'-phosphate. Since pyridoxal 5'-phosphate can be administered as a vitamin to man without any relevant side-effects its role as a physiological anti-aggregant of polymorphonuclear leukocytes warrants further investigation.
Schinella
M
M
Laboratorio di Chimica Clinica ed Ematologia, Ospedale Civile Maggiore, Verona, Italy.
Nicoli
M
M
Lippi
G
G
Chirumbolo
S
S
D000328:Adult; D002449:Cell Aggregation / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D009504:Neutrophils / Q000166:cytology* / Q000187:drug effects*; D011732:Pyridoxal Phosphate / Q000008:administration & dosage / Q000494:pharmacology* / Q000502:physiology; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology
D011732:Pyridoxal Phosphate; D013755:Tetradecanoylphorbol Acetate